Satellos Bioscience Inc. (MSLE)
$7.49+1.90%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $10M
- Beta
- 1.17
- P/E (TTM)
- -3.83
- Short % float
- 9.93%
- Days to cover
- 1.6
- SI change
- +28.2%
- 1W
- -11.88%
- 1M
- -25.47%
- vs SPY 1W
- -13.04%
- vs SPY 1M
- -28.46%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-43.6%
REV YoY-
ROE-72.7%
EPS YoY-
ROA-53.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-3.83
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B2.64
P/FCF-
EV/EBITDA-4.19
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO11.22
ND/EBITDA-
BETA1.17
Company news
FAQ
- What is LOPJLB’s current signal on MSLE?
- LOPJLB’s latest quantitative signal on Satellos Bioscience Inc. (MSLE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MSLE in?
- Satellos Bioscience Inc. (MSLE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Satellos Bioscience Inc. (MSLE) do?
- Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy …